Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excludedXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary diseaseXx_NEWLINE_xXPatients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral loadXx_NEWLINE_xXPatients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registrationXx_NEWLINE_xXPatients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration; patients who have completed curative therapy for HCV are eligible; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria:\r\n* CD4 counts >= 350 mm^3\r\n* Serum HIV viral load of < 25,000 IU/ml and\r\n* Treated on a stable antiretroviral regimenXx_NEWLINE_xXParticipant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection and/or active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA).Xx_NEWLINE_xXNegative screening test results for human immunodeficiency virus (HIV), hepatitis B and C; if positive results are not indicative of true active or chronic infection, the subjects can enter the study after discussion with the principal investigatorXx_NEWLINE_xXPatients with known active infections with human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B (HBV), and hepatitis C virus (HCV) infections will not be considered for this trial; HIV+ patients on combination antiretroviral therapy are ineligible; testing for HIV or hepatitis is not requiredXx_NEWLINE_xXPrior or current history of hepatitis B, hepatitis C or human immunodeficiency virusXx_NEWLINE_xXEvidence of severe or uncontrolled systemic diseases including active liver disease (other than malignancy), active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Exclusion crtieria Part CXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection, infectious hepatitis, type A, B or C, active hepatitis, or hepatic insufficiencyXx_NEWLINE_xXPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitisXx_NEWLINE_xX12. Known to be human immunodeficiency virus (HIV) positive, hepatitis B, or hepatitis C positive;Xx_NEWLINE_xXPatients with known active hepatitis (i.e., hepatitis B or C) or human immunodeficiency virus (HIV) with detectable viral load (history of HIV with undetectable viral load is allowed)Xx_NEWLINE_xXPreviously known infection with human immunodeficiency virus (HIV); or hepatitis B or hepatitis C infection.Xx_NEWLINE_xXHepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXAs judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus; screening for chronic conditions is not requiredXx_NEWLINE_xXActive hepatitis B virus (HBV) infectionXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXKnown or suspected chronic active Epstein-Barr virus (EBV) infection, acute or chronic hepatitis C virus (HCV) infectionXx_NEWLINE_xXSubject has an active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human T-lymphotropic virus (HTLV) as defined below:Xx_NEWLINE_xXKnown human immunodeficiency virus or active hepatitis C viral infectionXx_NEWLINE_xXPatients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.Xx_NEWLINE_xXKnown history of human immunodeficiency virus infection (HIV) or hepatitis C or active hepatitis B infection, unless the patient was diagnosed >10 years prior to enrollment and no evidence of active liver disease.Xx_NEWLINE_xXActive and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness; baseline viral assessment is not required in patients with no known infectionXx_NEWLINE_xXEXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virusXx_NEWLINE_xXEXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virusXx_NEWLINE_xXCurrent known active infection with HIV, hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXPositive serology for human immunodeficiency virus (HIV) or hepatitis C virus (HCV); presence in the serum of the antigen hemoglobin (HBs)Xx_NEWLINE_xXHas a known history of or screens positive for Human Immunodeficiency Virus (HIV), active chronic or acute Hepatitis B or Hepatitis C.Xx_NEWLINE_xXSubject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.Xx_NEWLINE_xXPatients seropositive or PCR positive for the human immunodeficiency virus (HIV). Patients with evidence of Hepatitis B or Hepatitis C PCR positivityXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitisXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infectionXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; similarly, patients with chronic or acute hepatitis C virus (HCV) or hepatitis B virus (HBV) infection are also ineligible; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowedXx_NEWLINE_xXNew York Heart Association (NYHA) stage III/IV congestive heart failure, arrhythmias not adequately controlled, active infections, or other significant co-morbidities [e.g. active central nervous system metastases and/or carcinomatous meningitis, active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C.Xx_NEWLINE_xXPositive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.Xx_NEWLINE_xXKnown to be seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)Xx_NEWLINE_xXActive infection, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen or hepatitis C.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function tests [LFTs] and undetectable viral loads are allowed)Xx_NEWLINE_xXPatients known to be seropositive for human immunodeficiency virus (HIV) and active hepatitis, even if liver function studies are in the eligible rangeXx_NEWLINE_xXIs test positive for hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) antibody.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapyXx_NEWLINE_xXKnown seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV)Xx_NEWLINE_xXNo known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C viral infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)Xx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXPrior or current history of hepatitis B, hepatitis C or human immunodeficiency virusXx_NEWLINE_xXPositive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus (HTLV).Xx_NEWLINE_xXNo known human immunodeficiency virus (HIV) positive, or active hepatitis infectionXx_NEWLINE_xXKnown active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrierXx_NEWLINE_xXPatients with known active human immunodeficiency virus (HIV), hepatitis (hep) B, or hep C infectionXx_NEWLINE_xXActive hepatitis or human immunodeficiency virus infectionXx_NEWLINE_xXHave a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis A, B, or C (screening is not required).Xx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXNegative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) DNAXx_NEWLINE_xXSubjects with known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excludedXx_NEWLINE_xXPHASE II EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excludedXx_NEWLINE_xXCurrent known active infection with HIV, hepatitis B virus, or hepatitis C virus.Xx_NEWLINE_xXSubject is seropositive for or has active viral infection with hepatitis B virus (HBV):Xx_NEWLINE_xXSubject is known to be seropositive for, or have an active infection with, hepatitis C virus (HCV).Xx_NEWLINE_xXAny positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus.Xx_NEWLINE_xXActive hepatitis B virus (HBV) infection (chronic or acute)Xx_NEWLINE_xXActive hepatitis C virus (HCV) infectionXx_NEWLINE_xXParticipant has a known history of human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV), or requires treatment with protease inhibitors (testing not mandatory).Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), active infection with hepatitis B virus (HBV), and/or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), active infection with hepatitis B virus (HBV), and/or hepatitis C virus (HCV)Xx_NEWLINE_xXActive human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C infection.Xx_NEWLINE_xXKnown chronic infections with human immunodeficiency virus (HIV), hepatitis B or C; participants with a history of resolved hepatitis A may be included in the trialXx_NEWLINE_xXAny known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXNo known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) seropositivity; testing is not required in absence of clinical suspicionXx_NEWLINE_xXHave a serious concomitant systemic disorder that would compromise the participant's ability to adhere to the protocol, including active or chronic infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment.Xx_NEWLINE_xXKnown chronic infection with human immunodeficiency virus (HIV) or viral hepatitisXx_NEWLINE_xXHuman immunodeficiency virus (HIV) or hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXKnown positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.Xx_NEWLINE_xXHas known human immunodeficiency virus (HIV) and/or Hepatitis B or C infection(s).Xx_NEWLINE_xXKnown active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus (HIV) infection.Xx_NEWLINE_xXPositive test for human immunodeficiency virus and/or active hepatitis B or hepatitis C or tuberculosisXx_NEWLINE_xXPositive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosisXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), interstitial lung disease, active Hepatitis B or Hepatitis C, or ?Grade 3 immune-related AE with prior immunotherapyXx_NEWLINE_xXKnown infection with Human Immunodeficiency Virus (HIV), and/or active infection with hepatitis B, or hepatitis C.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection or known history of tuberculosisXx_NEWLINE_xXKnown active hepatitis A, B, or C virus infectionXx_NEWLINE_xXActive hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXSerious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics with 2 weeks of study enrollmentXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the Investigator's opinion, makes it undesirable for the patient to participate in the trial OR which would jeopardize compliance with the protocol such as active infection (e.g., hepatitis B, hepatitis C or human immunodeficiency virus [HIV]). Screening for chronic conditions is not required.Xx_NEWLINE_xXEXCLUSION - PROCUREMENT: Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)Xx_NEWLINE_xXKnown immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled inter-current illnesses.Xx_NEWLINE_xXKnown to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatmentXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXKnown infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti hepatitis C virus positive)Xx_NEWLINE_xXHave a known human immunodeficiency virus (HIV) infection or known activated/reactivated hepatitis A, B, or C.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B virus (HBV) and hepatitis C virus (HCV)Xx_NEWLINE_xXActive hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXActive human immunodeficiency virus (HIV) or hepatitis B or C infectionXx_NEWLINE_xXPositive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus (HTLV).Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV or HCV infection, which will be allowed)Xx_NEWLINE_xXHave negative test result for human immunodeficiency virus (HIV) and hepatitis B or C testingXx_NEWLINE_xXParticipants with known history of human immunodeficiency virus (HIV) or active Hepatitis B or C virusXx_NEWLINE_xXSubjects with a known history of human immunodeficiency virus 1 and 2, human T lymphotropic virus 1, hepatitis B virus, or active hepatitis C virus.Xx_NEWLINE_xXThe patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.Xx_NEWLINE_xXPositive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; patients who have previously tested positive for hepatitis B core antibody may be eligible if they are confirmed to NOT have active disease and are on appropriate anti-viral therapy; no additional hepatitis or HIV testing is required for patients who have been evaluated during their induction and/or pre-transplant work-up and have had no clinical evidence of HIV, hepatitis B or hepatitis C since their last evaluationXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or known hepatitis C virus (HCV) infection or active hepatitis B.Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXHepatitis B and C negative (unless the result is consistent with prior vaccination or prior infection with full recovery); human immunodeficiency virus (HIV) negativeXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXActive infection with hepatitis C virus (HCV)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) infection:\r\n* Seropositive for HIV antibody\r\n* Seropositive for hepatitis C or positive for hepatitis B surface antigen (HbsAG)Xx_NEWLINE_xXOngoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection.Xx_NEWLINE_xXKnown seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) defined by polymerase chain reaction (PCR)Xx_NEWLINE_xXActive hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; hepatitis and HIV testing are not required prior to the start of treatmentXx_NEWLINE_xXActive infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)Xx_NEWLINE_xXDonors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infectionXx_NEWLINE_xXNo known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; testing is not required unless clinically suspectedXx_NEWLINE_xXKnown hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown infection of, or who test positive for, human immunodeficiency virus, hepatitis B virus or hepatitis C virus.Xx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or Hepatitis C infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positivity or evidence of active hepatitis C virus.Xx_NEWLINE_xXPatients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infectionsXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection or hepatitis B or C infection; HIV testing is not mandated and is to be performed at the discretion of the treating investigatorXx_NEWLINE_xXKnown immunodeficiency, human immunodeficiency virus (HIV) positivity, hepatitis B, or hepatitis CXx_NEWLINE_xXKnown active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of prior hepatitis B virus vaccination are eligibleXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)Xx_NEWLINE_xXPositive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV); hepatitis B is allowed only if viral load is undetectable and if on anti-hepatitis B therapy like entecavir; hepatitis C is allowed only if viral load is undetectable, and if the patient has received curative therapyXx_NEWLINE_xXKnown active human immunodeficiency virus (HIV) or hepatitis B or C infectionXx_NEWLINE_xXPatients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to trial registration. Patients who have completed curative therapy for HCV are eligible. Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria:\r\n* CD4 counts >= 350 mm^3\r\n* Serum HIV viral load of < 25,000 IU/ml and\r\n* Treated on a stable antiretroviral regimen.Xx_NEWLINE_xXActive infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV); patients with HBV and/or HCV sero-positivity only will be eligible, if nucleic acid amplification testing (NAT) is negativeXx_NEWLINE_xXKnown hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown human immunodeficiency virus or active hepatitis B or C viral infectionXx_NEWLINE_xXNo human immunodeficiency virus (HIV) infection or active hepatitis B or C.Xx_NEWLINE_xXKnown active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection.Xx_NEWLINE_xXKnown seropositive for or active viral infection with, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) positive patients on antiviral drugs are excluded due to the absence of previous experience with concurrent use of antiviral medications and the investigational drug product to be evaluated in the current study and possible for adverse pharmacokinetic and/or pharmacodynamic interactionsXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; HIV positive patients will be excluded due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infectionXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or known active infection including chronic active hepatitis B, hepatitis C and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on appropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment periodXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; active hepatitis B or C;Xx_NEWLINE_xXNegative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.Xx_NEWLINE_xXActive and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness (human immunodeficiency virus [HIV] testing is not required), including patients who have an active infection requiring systemic therapyXx_NEWLINE_xXPatients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.Xx_NEWLINE_xXAs judged by the Investigator, has any evidence of severe or uncontrolled diseases such as active bleeding diatheses, or has an active viral infection of human immunodeficiency virus (HIV), human papilloma virus (HPV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV)Xx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infectionXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not requiredXx_NEWLINE_xXPatients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registrationXx_NEWLINE_xXPatients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXHas active human immunodeficiency virus infection that is uncontrolled (increasing plasma HIV RNA viral load) with medication, or has an active hepatitis B or C infectionXx_NEWLINE_xXDocumented human immunodeficiency virus (HIV) infection or positive serology, active bacterial infections, serologic or polymerase chain reaction (PCR) evidence for active or chronic hepatitis B or hepatitis CXx_NEWLINE_xXEvidence of hepatitis B virus, hepatitis C virus or known HIV infectionXx_NEWLINE_xXKnown infection caused by human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXPositive serology for hepatitis B or C, or known human immunodeficiency virus infection (HIV)Xx_NEWLINE_xXActive uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infectionXx_NEWLINE_xXPatients with known active human immunodeficiency virus (HIV), hepatitis (Hep) B, or Hep C infection will be excluded; if not clinically indicated, the patients do not need to be testedXx_NEWLINE_xXEvidence of hepatitis B virus, hepatitis C virus or known HIV infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXHave a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment; patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligibleXx_NEWLINE_xXHas serious concomitant illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders; this includes human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B virus (HBV) and hepatitis C virus (HCV)Xx_NEWLINE_xXActive HIV, hepatitis C virus, or hepatitis B virus infection(s)Xx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXDonors who are human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infectionXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)Xx_NEWLINE_xXPatients with other viral infections are ineligible:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXHas active co-infection with HBV and hepatitis D virus (HDV)Xx_NEWLINE_xXSubject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or is known to be a carrier of hepatitis B or C.Xx_NEWLINE_xXSubjects with known human immunodeficiency virus (HIV), acute chronic hepatitis B virus surface antigen (HBsAg) or hepatitis C virus. (HIV-positive subjects are ineligible because of the potential for pharmacokinetic interactions of antiviral therapy with IACS-010759.)Xx_NEWLINE_xXActive and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV testing is not required)Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXIs human immunodeficiency virus (HIV) positive or has evidence of active hepatitis C virus or active hepatitis B virus; if initial test shows a positive result, no further testing will be doneXx_NEWLINE_xXKnown positive test for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis A, hepatitis B, hepatitis C, or cytomegalovirus (CMV)Xx_NEWLINE_xXPatients with clinically evident human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excludedXx_NEWLINE_xXKnown or active human immunodeficiency virus (HIV) infection or active hepatitis B or C viral infectionXx_NEWLINE_xXActive infection requiring systemic therapy including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permittedXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)Xx_NEWLINE_xXPatients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) positivity or active hepatitis C or B - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or a history of active hepatitis B or C as evidenced by laboratory abnormalities in addition to positive serology; testing is not required for patients not suspected of having these conditionsXx_NEWLINE_xXActive severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus (testing not required prior to enrollment)\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parametersXx_NEWLINE_xXPatients known to have acute or chronic active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C.Xx_NEWLINE_xXKnown evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)Xx_NEWLINE_xXPatients with a known chronic immunocompromised state, human immunodeficiency virus (HIV) infection, or active hepatitis B or C infectionXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate CD4 count, not requiring antiretroviral medication, may be enrolledXx_NEWLINE_xXHuman immunodeficiency virus (HIV), active hepatitis B or CXx_NEWLINE_xXAny evidence of a severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including hepatitis B, hepatitis C, human immunodeficiency virus [HIV]), active bleeding diatheses or renal transplantXx_NEWLINE_xXKnown active hepatitis A, B or C virus infectionXx_NEWLINE_xXAcute hepatitis or known human immunodeficiency virus (HIV)Xx_NEWLINE_xXParticipants with progressive neurological dysfunction that would confound the evaluation of neurological and other toxicities; any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any participant with known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXPatients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatmentXx_NEWLINE_xXPatients with active hepatic disease, liver cirrhosis, or known hepatitis B virus (HBV)/hepatitis C virus (HCV) infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) seropositivity, or active hepatitis B or C infection based on testing performed within 4 weeks of enrollment.Xx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (hepatitis B surface antigen [HBsAg] positive) or hepatitis C virus (anti-HCV positive).Xx_NEWLINE_xXPatients with conditions requiring immunosuppressive medications or chronic infections (including human immunodeficiency virus [HIV] infection, hepatitis B and C)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; active hepatitis B or CXx_NEWLINE_xXSerious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollmentXx_NEWLINE_xXCRITERIA FOR SCREENING: Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXActive bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) -related illnessXx_NEWLINE_xXHave any condition or illness that, in the opinion of the investigator would compromise patient safety or interfere with evaluation of the study drug (including but not limited to human immunodeficiency virus [HIV] and hepatitis C virus [HCV])Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)Xx_NEWLINE_xXKnown to have acute or chronic active hepatitis B infection, hepatitis C infection, or known to have human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligibleXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; NOTE: HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) testing is not requiredXx_NEWLINE_xXHuman immunodeficiency virus (HIV) seropositive, or active hepatitis A, B, or C infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligibleXx_NEWLINE_xXUncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXKnown hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.Xx_NEWLINE_xXActive human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or tuberculosis infection; patients with a history of cleared hepatitis C (undetectable viral loads) are allowedXx_NEWLINE_xXActive uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXNegative human immunodeficiency virus (HIV), hepatitis B and C, and tuberculosis (TB) testXx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis B or C documented infectionsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or active hepatitis A, B, or CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infectionXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screeningXx_NEWLINE_xXActive hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXActive hepatitis B, active hepatitis C, or positive for human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excludedXx_NEWLINE_xXInfection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virusXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV) infection or active hepatitis B or CXx_NEWLINE_xXKnown active infection with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV. Cleared HBV/HCV infection is not an exclusion, nor is HIV infection with cluster of differentiations 4 (CD4) counts >500 and an undetectable viral load.Xx_NEWLINE_xXDONOR: Positivity for HIV, hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]), human T-cell lymphotropic virus (HTLV-I/II)Xx_NEWLINE_xXActive systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])Xx_NEWLINE_xXAny history of human immunodeficiency virus (HIV) or hepatitis B infectionXx_NEWLINE_xXHas evidence of active hepatitis B virus or hepatitis C virusXx_NEWLINE_xXPatient has a known history of human immunodeficiency virus (HIV) infection or chronic, active hepatitis B (testing not mandatory)Xx_NEWLINE_xXAs judged by the investigator, has any evidence of severe or uncontrolled systemic diseases such as active bleeding diatheses, is positive for human immunodeficiency virus (HIV), or has active hepatitis B virus (HBV) and/or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infectionXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); subjects who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXInfection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; active hepatitis B or CXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown history of human immunodeficiency virus infection or an active hepatitis B or C virus infection (exception: this criteria does not apply to patients with cervical/anal tumours enrolling in Cohort 6)Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infectionXx_NEWLINE_xXKnown prior or current history of human immunodeficiency virus (HIV) and/or hepatitis B/CXx_NEWLINE_xXKnown active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required)Xx_NEWLINE_xXNo human immunodeficiency virus (HIV) infection or active hepatitis B or CXx_NEWLINE_xXEvidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Human Herpes Virus-6 (HHV-6), Hepatitis Virus (HBV), or Hepatitis C Virus (HCV) based on assessment by the treating physician.Xx_NEWLINE_xXKnown history of a positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infectionXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXSerious infections including a history of active hepatitis B, hepatitis C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown seropositivity for, or active viral infection with, human immunodeficiency virus (HIV), hepatitis B virus (HBV) (unless due to vaccination), or hepatitis C virus (HCV); HIV-positive patients on combination antiretroviral therapy are ineligibleXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV)Xx_NEWLINE_xXDONOR: Chronic viral infection including active hepatitis B, hepatitis C, HIV, or human T-lymphotropic virus (HTLV)-1/2Xx_NEWLINE_xXSubjects who active hepatitis B or C, or human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infectionXx_NEWLINE_xXActive hepatitis B (hepatitis B virus [HBV]) or C (hepatitis C virus [HCV]) infection (negative serology required excluding those with are seropositive due to prior vaccination) and/or known history of human immunodeficiency virus (HIV)Xx_NEWLINE_xXActive hepatitis, known human immunodeficiency virus (HIV), or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroidsXx_NEWLINE_xXNo known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis CXx_NEWLINE_xXActive infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)Xx_NEWLINE_xXCurrent or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection or hepatitisXx_NEWLINE_xXKnown history of active tuberculosis (TB), human immunodeficiency virus (HIV) 1/2, hepatitis B or hepatitis CXx_NEWLINE_xXTrue positive test results for human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXHuman immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection due to risk of progression while receiving immunosuppressive chemotherapyXx_NEWLINE_xXHuman immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; HIV positive patients will be excludedXx_NEWLINE_xXHave a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids.Xx_NEWLINE_xXUncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B or C infectionXx_NEWLINE_xXAny positive history for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), human T-cell lymphotropic virus (HTLV), hepatitis B or hepatitis C virus indicating acute or chronic infectionXx_NEWLINE_xXActive infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)Xx_NEWLINE_xXKnown positive test for human immunodeficiency virus infection (HIV), or active hepatitis B or hepatitis C infection.Xx_NEWLINE_xXKnown seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B vaccine are eligibleXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis CXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXKnown active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown active acute or chronic infection including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitisXx_NEWLINE_xXKnown active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXHas a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive and on highly active antiretroviral therapy (HAART), and/or hepatitis B or C on treatmentXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or active hepatitis A, B or CXx_NEWLINE_xXKnown active hepatitis B virus (HBV), human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible)Xx_NEWLINE_xXKnown active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or cytomegalovirus (CMV)Xx_NEWLINE_xXHas a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), active hepatitis B or hepatitis CXx_NEWLINE_xXHas a known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosisXx_NEWLINE_xXDONOR: Active human immunodeficiency virus (HIV) or hepatitis B or C infectionXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection (note: if not suspected, testing is not required at baseline)Xx_NEWLINE_xXActive uncontrolled infection; presence of latent or medication-controlled human immunodeficiency virus (HIV) and/or viral hepatitis is allowedXx_NEWLINE_xXKnown positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infectionXx_NEWLINE_xXOngoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXSubjects must not have active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; testing is not required as part of this studyXx_NEWLINE_xXKnown hepatitis B virus, hepatitis C virus or HIV infectionXx_NEWLINE_xXKnown immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, hepatitis B or hepatitis CXx_NEWLINE_xXActive infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).Xx_NEWLINE_xXBe on immunosuppressive therapy or have human immunodeficiency virus (HIV) infection or active hepatitis B or CXx_NEWLINE_xXPatients with known hepatitis B or C or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.Xx_NEWLINE_xXPatients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligibleXx_NEWLINE_xXHas known active infection with hepatitis B virus or hepatitis C virusXx_NEWLINE_xXActive viral hepatitis or active human immunodeficiency virus (HIV) infection. Asymptomatic positive serology is not exclusionary.Xx_NEWLINE_xXActive hepatitis A, B, or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic disease, including, but not limited to, ongoing or active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)Xx_NEWLINE_xXNo known history of human immunodeficiency virus (HIV) 1 and 2, human T-lymphotropic virus (HTLV)-1, or active hepatitis B or hepatitis CXx_NEWLINE_xXKnown active hepatitis B infection, known history of hepatitis C or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXHuman immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), hepatitis B virus (HBV), and hepatitis C virus (HCV) negativeXx_NEWLINE_xXMust not have evidence of previous or current infection with hepatitis B virusXx_NEWLINE_xXSubject has a known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)Xx_NEWLINE_xXHave a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; active hepatitis B or CXx_NEWLINE_xXKnown positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.Xx_NEWLINE_xXDONOR: Hepatitis A, B and C, HIV 1 and 2, human T-lymphotropic virus (HTLV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), West Nile virus, Syphilis Treponema, T cruzi (Chagas), cytomegalovirus (CMV), and the MPX nucleic acid test (NAT) individual donor testing (IDT) (human immunodeficiency virus [HIV]/hepatitis C virus [HCV]/hepatitis B virus [HBV]) will be tested as per national standard of care guidelines for transplant donors; donors who are HIV positive will be excluded; donors who are positive by serology for Hepatitis B or C are eligible as long as polymerase chain reaction (PCR) for ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) is negativeXx_NEWLINE_xXCurrent or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXOngoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXCurrent or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown active hepatitis C virus, or known active hepatitis B virusXx_NEWLINE_xXActive hepatitis B or hepatitis C or known human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV); active hepatitis B (HBV) or hepatitis C (HCV) infectionXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positivityXx_NEWLINE_xXKnown ongoing or known active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXActive hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or hepatitis CXx_NEWLINE_xXKnown sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXAn existing diagnosis of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditionsXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive (recipients who are positive for hepatitis B [hepatitis B virus (HBV)], hepatitis C [hepatitis C virus (HCV)] or human T-cell lymphotropic virus [HTLV]-I/II are not excluded from participation)Xx_NEWLINE_xXKnown active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be curedXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis CXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotropic virus 1 (HTLV1) and/or HTLV2Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infectionXx_NEWLINE_xXPatient has known human immunodeficiency virus (HIV) or hepatitis C infection; baseline testing for HIV or hepatitis C is not requiredXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicionXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis CXx_NEWLINE_xXResearch participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollmentXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis CXx_NEWLINE_xXSerious illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders; this includes human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B virus (HBV) and hepatitis C virus (HCV)Xx_NEWLINE_xXKnown active human immunodeficiency virus (HIV), hepatitis B or C or infection; exception for patients with hepatitis B on antivirals and low viral load, to be determined at the discretion of the investigatorXx_NEWLINE_xXActive and uncontrolled infection including but not limited to known infection with human immunodeficiency virus (HIV), active hepatitis B, or hepatitis CXx_NEWLINE_xXSeroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus type I (HTLV I) or II, hepatitis B virus (HBV), hepatitis C virus (HCV)Xx_NEWLINE_xXHas a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infectionXx_NEWLINE_xXUncontrolled infection, including human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV)-1, hepatitis B or hepatitis C viremiaXx_NEWLINE_xXKnown hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXKnown hepatitis B virus, hepatitis C virus or HIV infectionXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; active hepatitis B or CXx_NEWLINE_xXActive infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy, human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis CXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B, hepatitis C and human t-lymphotropic virus (HTLV)Xx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXPositivity for human immunodeficiency virus (HIV)-1/HIV-2, Hepatitis B virus, and Hepatitis C virus active infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis B, hepatitis CXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV)-positive or have active hepatitis B or CXx_NEWLINE_xXHistory of chronic or recurrent infection including but not limited to human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or with known active infectious hepatitis, type A, B or CXx_NEWLINE_xXUncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy, excluding chronic asymptomatic viral infections (e.g., human papillomavirus [HPV], BK virus, hepatitis C virus [HCV], etc.)Xx_NEWLINE_xXKnown to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)Xx_NEWLINE_xXDONOR: Must be free from risk factors for, and no clinical evidence of, infection due to relevant communicable disease agents and diseases including: human immunodeficiency virus; hepatitis B virus; hepatitis C virus; human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease; treponema pallidum and human T-cell lymphotropic virus (HTLV) 1 and 2Xx_NEWLINE_xXKnown positive for human immunodeficiency virus-1 (HIV-1), or active infection with hepatitis-B or -CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or hepatitis B positivity or prior progressive multifocal leukoencephalopathy (PML)Xx_NEWLINE_xXKnown active infection with HIV, hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV)-I, hepatitis B, or hepatitis CXx_NEWLINE_xXPositivity for human immunodeficiency virus (HIV)-1/HIV-2, hepatitis B virus, and hepatitis C virus active infectionXx_NEWLINE_xXPatients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXIn suspected patients no active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXActive infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)Xx_NEWLINE_xXActive severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence\r\nof cirrhosis AND the patient’s liver function tests fall within the parameters setXx_NEWLINE_xXPatients must be human immunodeficiency virus (HIV) negative, and have negative serologies for hepatitis CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C\r\n* Note: patients who have a history of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are eligible, however, they must receive prophylactic antiviral therapy for 1-2 weeks prior to receiving study drugXx_NEWLINE_xXKnown sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXPatients with active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive or symptomatic infection including human immunodeficiency virus (HIV), viral hepatitis or chronic liver diseaseXx_NEWLINE_xXKnown active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.Xx_NEWLINE_xXKnown seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXHave an ongoing or active infection, including but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history.Xx_NEWLINE_xXPatients with known active human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXActive infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), human T-cell lymphotropic virus (HBV), hepatitis C virus (HCV) (can be pending at this time)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection, active hepatitis B or C infection, or evidence of liver cirrhosisXx_NEWLINE_xXHepatitis C infection, chronic infection with hepatitis B, infection with human immunodeficiency virus (HIV), or evidence of hepatic insufficiencyXx_NEWLINE_xXA known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatmentXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection are ineligibleXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), or known active hepatitis B or C infection.Xx_NEWLINE_xXActive infection including human immunodeficiency virus (HIV) and untreated hepatitis B, and hepatitis C. Screening for chronic conditions is not required.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown hepatitis B virus, hepatitis C virus or HIV infectionXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.Xx_NEWLINE_xXPositive test for hepatitis B hepatitis C, and / or human immunodeficiency virus (HIV) during screening, or within 3 months prior to first dose of study treatmentXx_NEWLINE_xXAny evidence of active infection including active Hepatitis B, Hepatitis C or human immunodeficiency virusXx_NEWLINE_xXSubjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocolXx_NEWLINE_xXKnown positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), or hepatitis C.Xx_NEWLINE_xXPatients with known human immunodeficiency virus, active hepatitis B or active hepatitis CXx_NEWLINE_xXNo known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection.Xx_NEWLINE_xXSubjects with known active hepatitis B or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection.Xx_NEWLINE_xXKnown positive test result for human immunodeficiency virus or active hepatitis B or C virus infectionXx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Known infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)Xx_NEWLINE_xXHas known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection based on positive tests during ScreeningXx_NEWLINE_xXEvidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.Xx_NEWLINE_xXKnown active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.Xx_NEWLINE_xXSubject is positive for human immunodeficiency virus (HIV-1) chronic or active hepatitis B, or active hepatitis A or CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.Xx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXKnown hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.Xx_NEWLINE_xXChronic hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive, that might affect host immunityXx_NEWLINE_xXOngoing, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXRENAL & BLADDER: Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infectionXx_NEWLINE_xXNegative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virusXx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positiveXx_NEWLINE_xXPatients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or CXx_NEWLINE_xXKnown history of human immunodeficiency virus or infection with hepatitis requiring antiviral therapyXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or hepatitis C (baseline testing is not required)Xx_NEWLINE_xXSubject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibody (unless treated curatively)Xx_NEWLINE_xXNo infection with human immunodeficiency virus (HIV) and no known history of hepatitis B or hepatitis C virus indicating acute or chronic infection or active tuberculosis (TB)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; subjects with laboratory evidence of cleared HBV and HCV infection will be permittedXx_NEWLINE_xXParticipants who have a known active infection requiring systemic therapy, including human immunodeficiency virus (HIV), hepatitis B, and hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)Xx_NEWLINE_xXUncontrolled infection with human immunodeficiency virus (HIV) or chronic hepatitis B or C.Xx_NEWLINE_xXPositive human immunodeficiency virus (HIV) test, active tuberculosis, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXParticipant has an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C antibodies)Xx_NEWLINE_xXOther viral infections:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXKnown active infection with human immunodeficiency virus, hepatitis B, or hepatitis CXx_NEWLINE_xXEvidence of any of the following conditions per subject self-report or medical chart review\r\n* Any prior invasive malignancy within 5 years of enrollment that may affect outcome of study\r\n* Any non-invasive malignancy not treated with curative intent or with known active disease within 5 years before enrollment that may affect outcome of study\r\n* Major surgery or significant traumatic injury occurring within 4 weeks before enrollment\r\n* Active infection with hepatitis B virus or hepatitis C virus\r\n* Known infection with human immunodeficiency virus (HIV)\r\n* Active infection requiring IV anti-infective therapyXx_NEWLINE_xXActive infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone corticosteroid) use contraindicatedXx_NEWLINE_xXActive Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXActive hepatitis B virus (HBV) infectionXx_NEWLINE_xXKnown history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXOther viral infections\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollmentXx_NEWLINE_xXPatients with known active hepatitis B or C or human immunodeficiency virus (HIV) infection or with history of tuberculosisXx_NEWLINE_xXKnown chronic hepatitis B or C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown hepatitis B virus (HBV) or hepatitis C virus (HBV) infectionXx_NEWLINE_xXPatient is known to be human immunodeficiency virus (HIV) positive, or have chronic or active hepatitis B (core- or surface antigen-positive) or active hepatitis C infectionXx_NEWLINE_xXKnown chronic infection with human immunodeficiency virus, hepatitis B, or hepatitis C.Xx_NEWLINE_xXHepatitis B, hepatitis C, and human immunodeficiency virus (HIV) serology-positive (or known history of HIV seropositive status) participants are ineligible; hepatitis B, hepatitis C, and HIV serology-positive individuals were excluded from the pivotal pembrolizumab clinical trial in melanoma, so safety of this drug in this setting is unknownXx_NEWLINE_xXPatients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) due to potentially increased risk of mithramycin toxicity in this populationXx_NEWLINE_xXPatients with chronic viral illnesses such as human immunodeficiency virus (HIV)-positivity and active hepatitis B or C are ineligibleXx_NEWLINE_xXPatients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infectionsXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis CXx_NEWLINE_xXKnown active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowedXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) or hepatitis, or known active cytomegalovirus (CMV), Epstein–Barr virus (EBV) or any other viral illness requiring treatment are ineligibleXx_NEWLINE_xXKnown active human immunodeficiency virus (HIV) or hepatitis A, B, or C virus infectionXx_NEWLINE_xXKnown chronic infections with human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) seropositivityXx_NEWLINE_xXHuman immunodeficiency virus (HIV) and hepatitis c negative (serology)Xx_NEWLINE_xXPatient has a current active infectious disease or known positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or hepatitis A virus (HAV)Xx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients must have negative testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) within 4 weeks prior to randomizationXx_NEWLINE_xXHave known seropositivity for human immunodeficiency virus, hepatitis C virus, hepatitis B surface antigen, or syphilis; does not require serologic confirmation as a study procedureXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXPatients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excludedXx_NEWLINE_xXActive severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set aboveXx_NEWLINE_xXCurrent infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patients will have serologic testing performed during screening for HIV and hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient’s statusXx_NEWLINE_xXSubjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection; subjects with chronic HBV or HCV infection are eligible at the investigator’s discretion if the subject is considered non-infectious based on serological markersXx_NEWLINE_xXSubjects with known history of cirrhosis, human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXKnown hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)Xx_NEWLINE_xXHas a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (no additional laboratory tests for HIV, hepatitis [Hep] B, or Hep C are required for screening)Xx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) infection or active hepatitis B or hepatitis CXx_NEWLINE_xXActive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXOngoing or active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXOngoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitisXx_NEWLINE_xXKnown hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXKnown active hepatitis B infection, known active hepatitis C infection, or known human immunodeficiency virus (HIV) carrierXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)Xx_NEWLINE_xXKnown hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (unless cleared) will be excludedXx_NEWLINE_xXWith human immunodeficiency virus (HIV)-positivity or active infectious hepatitisXx_NEWLINE_xXPatients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excludedXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXHuman immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) infection: \r\n* Seropositive for HIV antibody \r\n* Seropositive for hepatitis C or positive for hepatitis B surface antigen (HbsAG)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B or C-positive patients (active, previously treated or both)Xx_NEWLINE_xXA known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune\n             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as\n             determined by medical history.Xx_NEWLINE_xXPatient must not be known to be human immunodeficiency virus (HIV)-positive, hepatitis B-positive, or hepatitis C-positive (with the exception of chronic or cleared hepatitis B virus [HBV] or hepatitis C virus [HCV] infection, which will be allowed)Xx_NEWLINE_xXPatients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness will be excluded from the study; HIV-positive patients on combination antiretroviral therapy are ineligibleXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or known history of active hepatitis B or C infectionXx_NEWLINE_xXPatients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illnessXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) disease or active viral hepatitisXx_NEWLINE_xXPatients who have human immunodeficiency virus (HIV) or hepatitis C; patients would not be excluded for hepatitis B surface antigen positivity if on lamivudine or entecavirXx_NEWLINE_xXPatients who have human immunodeficiency virus (HIV) or hepatitis C; patients would not be excluded for hepatitis B surface antigen positivity if on lamivudineXx_NEWLINE_xXActive infection with hepatitis A, B or C virusXx_NEWLINE_xXPatients known to be seropositive for human immunodeficiency virus (HIV) and active hepatitis, even if liver function studies are in the eligible rangeXx_NEWLINE_xXPatient must not be known to have human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with participation in this study; patients will be tested for hepatitis B or C or HIV infection during screening if they are considered by the investigator to be at higher risk for these infections and have not been previously testedXx_NEWLINE_xXHuman immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXKnown seropositive for, or history of, active Human Immunodeficiency Virus (HIV) Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)Xx_NEWLINE_xXKnown infection with human immunodeficiency virus, or active hepatitis B or C, or other active clinically relevant liver disease.Xx_NEWLINE_xXPositive test for hepatitis B, C or HIV (Human Immunodeficiency Virus) virusXx_NEWLINE_xXHas controlled infection by Hepatitis B Virus (HBV).Xx_NEWLINE_xXSubjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.Xx_NEWLINE_xXHas a known Human Immunodeficiency Virus (HIV), or a known, active Hepatitis B (HBV), or a known, active Hepatitis C (HCV) infection.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), or Hepatitis B or C.Xx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.Xx_NEWLINE_xXKnown active hepatitis C virus, or known active hepatitis B virusXx_NEWLINE_xXKnown active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections or positive human immunodeficiency virus (HIV) antibody results. Patients with sustained virologic response to HCV treatment or immunity to HBV from prior infection without cirrhosis may be included.Xx_NEWLINE_xXEvidence of active hepatitis B (HepB), hepatitis C (HepC), or Human Immunodeficiency Virus (HIV) infection.Xx_NEWLINE_xXPatients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registrationXx_NEWLINE_xXPatients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) or active infection with hepatitis C virus or hepatitis B virus (testing is not mandatory)Xx_NEWLINE_xXIs positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or known active hepatitis B or hepatitis C infection for participants not receiving obinutuzumab pretreatmentXx_NEWLINE_xXActive or prior history of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.Xx_NEWLINE_xXPatients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitisXx_NEWLINE_xXThe patient has known positive status for human immunodeficiency virus (HIV) active or chronic Hepatitis B or Hepatitis C.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) seropositivity, acute or chronic active hepatitis B or C infection, or other serious chronic infection requiring ongoing treatmentXx_NEWLINE_xXOngoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.Xx_NEWLINE_xXSignificant life-threatening extra-hepatic disease, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be human immunodeficiency virus (HIV) positive or have acute hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown active infection with HIV or Hepatitis B or C virusXx_NEWLINE_xXEvidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.Xx_NEWLINE_xXKnown hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXHas evidence of interstitial lung disease, active non-infectious pneumonitis, a known additional malignancy that is progressing or requires active treatment, an active infection requiring intravenous systemic therapy, an active autoimmune disease that has required systemic therapy, a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infectionXx_NEWLINE_xXEvidence for infection including wound infections, Human Immunodeficiency Virus (HIV) or any type of HepatitisXx_NEWLINE_xXPatients must not have known human immunodeficiency virus (HIV), hepatitis B or C positivityXx_NEWLINE_xXSubjects is positive for human immunodeficiency virus (HIV); chronic or active hepatitis B or active hepatitis A, or CXx_NEWLINE_xXHave known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (A,B, or C).Xx_NEWLINE_xXSubject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded.Xx_NEWLINE_xXKnown human immunodeficiency virus, viral hepatitis, or tuberculosis positivityXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infectionXx_NEWLINE_xXClinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection.Xx_NEWLINE_xXPositive for human immunodeficiency virus (HIV), Hepatitis B or CXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or CXx_NEWLINE_xXIs positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or CXx_NEWLINE_xXKnown active or chronic hepatitis B or C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXActive viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.Xx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C (known from the existing medical record)Xx_NEWLINE_xXSeropositive for human immunodeficiency virus, hepatitis B, or hepatitis CXx_NEWLINE_xXHave active or uncontrolled clinically serious hepatitis B virus or hepatitis C virus infection.Xx_NEWLINE_xXKnown active hepatitis B or C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV) infection, active hepatitis B (chronic or acute), or hepatitis C infectionXx_NEWLINE_xXKnown infection with HIV or chronic infection with hepatitis B virus or hepatitis C virusXx_NEWLINE_xXKnown seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV).Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or chronic or active hepatitis B or hepatitis C requiring treatment with antiviral therapy.Xx_NEWLINE_xXEvidence of hepatitis B virus, hepatitis C virus or known HIV infectionXx_NEWLINE_xXHIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infectionXx_NEWLINE_xXSeropositive for or active viral infection with hepatitis B virus (HBV):Xx_NEWLINE_xXKnown seropositive for or active infection with hepatitis C virus (HCV)Xx_NEWLINE_xXClinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virusXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;Xx_NEWLINE_xXEXCLUSION FOR COLLECTION OF T CELLS/PBMCS: Patients with active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis BXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B vaccine are eligibleXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive patients or hepatitis B or C positive patientsXx_NEWLINE_xXHuman papilloma virus-associated cancers\r\n* Histologically proven squamous carcinoma of the anal canal, penile, vaginal, vulva, or refractory cervical cancer with progression or intolerance to at least one treatment regimen including cisplatin or carboplatin will be enrolled; human papilloma virus (HPV) confirmation is not required\r\n* Patients must have metastatic disease not amenable to surgical resection\r\n* If human immunodeficiency virus (HIV)+ positive, all patients infected with human immunodeficiency virus (HIV) and CD4+ T cell count > 400 cells/mm^3 may be eligible for study\r\n* Patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above; patients must be followed by a hepatologist during the course of this studyXx_NEWLINE_xXActive uncontrolled infection. Active hepatitis B or C virus (HBV or HCV), or human immunodeficiency virus (HIV)infection.Xx_NEWLINE_xXPatients with known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), active hepatitis C virus, active hepatitis B\r\nvirus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicatedXx_NEWLINE_xXKnown acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXPositive human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXSubject who has known seropositivity for or active infection for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXHuman immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosisXx_NEWLINE_xXKnown history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.Xx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or CXx_NEWLINE_xXSeropositive for human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) per patient historyXx_NEWLINE_xXActive viral hepatitis or active human immunodeficiency virus infectionXx_NEWLINE_xXSubjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self-reportXx_NEWLINE_xXSubject has a known history of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion; for guidance in defining active infection for hepatitis B, please refer to the World Health Organization (WHO) guidelinesXx_NEWLINE_xXPatient has a known history of human immunodeficiency virus (HIV) (testing not mandatory), active hepatitis B or C infectionXx_NEWLINE_xXKnown active hepatitis C virus, or known active hepatitis B virusXx_NEWLINE_xXUncontrolled infectious diseases - requires negative tests for clinically suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV).Xx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (B or C)Xx_NEWLINE_xXActive human immunodeficiency virus (HIV), Hepatitis B Virus (HBV) or hepatitis C virus (HCV) infections at the time of screening. Subjects with laboratory evidence of HCV clearance may be enrolled.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or human T-lymphotropic virus (HTLV) I/II infectionsXx_NEWLINE_xXActive infection with hepatitis B or C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXHave active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies). Screening is not required for enrollment.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXSubjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self reportXx_NEWLINE_xXKnown severe and/or uncontrolled medical disorder that would impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease, human immunodeficiency virus [HIV], hepatitis B virus [HBV], hepatitis C virus [HCV], or active infection)Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown to be HIV positive, active hepatitis C virus, or active hepatitis B virusXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infectionXx_NEWLINE_xXKnown HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivationXx_NEWLINE_xXKnown seropositive for or active viral infection with hepatitis B virus (HBV) or/and human immunodeficiency virus (HIV).Xx_NEWLINE_xXKnown history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXPatients with active infections including uncontrolled human immunodeficiency virus (HIV) infection, active hepatitis B, C, or any other symptomatic systemic infection requiring active therapy will be excluded from studyXx_NEWLINE_xXConfirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitisXx_NEWLINE_xXHistory of hepatitis B or C, human immunodeficiency virus (HIV), tuberculosis or a chronic infection of any typeXx_NEWLINE_xXPatients with fever or any active systemic infections, including known human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive or active infection requiring treatment (except for hepatitis virus)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.Xx_NEWLINE_xXInfection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virusXx_NEWLINE_xXActive infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)Xx_NEWLINE_xXNegative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was done within the past three months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent for HIV testingXx_NEWLINE_xXKnown immunodeficiency or human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; antibody to hepatitis B or C without evidence of active infection may be allowedXx_NEWLINE_xXHave active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment or have an active infection that is clinically serious in the investigator's opinion.Xx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or hepatitis B or C per institutional standard of careXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), or active hepatitis B or hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXKnown positive status for human immunodeficiency virus or active or chronic Hepatitis B or Hepatitis C.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, or life-threatening illnesses unrelated to cancer.Xx_NEWLINE_xXHuman Immunodeficiency Virus (HIV), or active Hepatitis C (HCV) virus. Escalation: active Hepatitis B (HBV); Expansion: Patients with Chronic HBV currently on medication will not be excluded.Xx_NEWLINE_xXKnown active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection on antiviral treatmentXx_NEWLINE_xXHepatitis B or C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXActive or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection (including undetectable viral loads while on antiviral therapy) and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowedXx_NEWLINE_xXPositive screening tests for human immunodeficiency virus (HIV), hepatitis B virus (Hep B), and hepatitis C virus (Hep C). If positive results are not indicative of true active or chronic infection, the patient can be treated.Xx_NEWLINE_xXSeropositive or active viral infection with hepatitis B virus, human immunodeficiency virus or hepatitis C virus.Xx_NEWLINE_xXKnown seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXActive infection with hepatitis B or C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXActive infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)Xx_NEWLINE_xXActive infection with human immunodeficiency virus (HIV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXPatients with known active hepatitis B virus or hepatitis C virus acute or chronic infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) and/or active Hepatitis B or C infectionsXx_NEWLINE_xXOngoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitisXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXSubjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment.Xx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients confirmed to be human immunodeficiency virus (HIV) positive or have active viral hepatitisXx_NEWLINE_xXKnown positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or CXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive ( i.e. hepatitis B core antibody positive; quantitative deoxyribonucleic acid [DNA] negative) are eligible with appropriate prophylaxisXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicatedXx_NEWLINE_xXSubjects with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infectionXx_NEWLINE_xXActive hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXCurrent or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)Xx_NEWLINE_xXThe participant has active infection requiring systemic therapy, including active tuberculosis or known history of infection with the human immunodeficiency virus (HIV 1/2 antibodies), or hepatitis B (e.g., HBsAg reactive) and/or C virus (e.g., HCV RNA [qualitative] is detected).Xx_NEWLINE_xXKnown seropositive for or active human immunodeficiency virus (HIV) infection or hepatitis B or C viral infection; patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXKnown diagnosis of human immunodeficiency virus (HIV) or hepatitis C (testing is not mandatory)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients or with history of hepatitis or with current chronic or active hepatitis; a past history of hepatitis A is allowedXx_NEWLINE_xXKnown hepatitis B or C virus, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBC and HCV infection, which will be allowed)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B.Xx_NEWLINE_xXHas a known history of Human Immunodeficiency Virus (HIV) or Hepatitis C (baseline testing is not required).Xx_NEWLINE_xXActive or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus.Xx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), active Hepatitis B or CXx_NEWLINE_xXKnown active human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)Xx_NEWLINE_xXClinically active infection as judged by the treating investigator (? Grade 2 by CTCAE v4) including known human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXKnown seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis CXx_NEWLINE_xXSubjects with a known history of hepatitis B or C or human immunodeficiency (HIV) infection.Xx_NEWLINE_xXActive infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV);Xx_NEWLINE_xXPositive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosisXx_NEWLINE_xXEvidence of hepatitis B virus, hepatitis C virus or known HIV infectionXx_NEWLINE_xXAny evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).Xx_NEWLINE_xXKnown hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)Xx_NEWLINE_xXPatients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded.Xx_NEWLINE_xXDONOR: No positive testing for viral infection (hepatitis B surface antigen [HbsAg], human immunodeficiency virus (HIV), hepatitis C virus [HCV])Xx_NEWLINE_xXKnown sero-positive for active or past viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXTrue positive test results for human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicionXx_NEWLINE_xXActive infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)Xx_NEWLINE_xXImmunocompromised subjects or those with autoimmune conditions, active hepatitis or positive for human immunodeficiency virus (HIV)Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).Xx_NEWLINE_xXParticipant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis CXx_NEWLINE_xXActive hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.Xx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or active hepatitis B or C; baseline testing is not requiredXx_NEWLINE_xXKnown hepatitis B virus, hepatitis C virus or HIV infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.Xx_NEWLINE_xXPatients must be test negative for human immunodeficiency virus (HIV), hepatitis B and CXx_NEWLINE_xXSubject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or hepatitis C virus requiring treatmentXx_NEWLINE_xXParticipants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXKnown diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.Xx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapyXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXPositive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosisXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXSubjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.Xx_NEWLINE_xXKnown seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXIs known to have human immunodeficiency virus (HIV) or has active hepatitis C virus (HCV), or active hepatitis B virus (HBV)Xx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active or carriers)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B and hepatitis C infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.Xx_NEWLINE_xXPositive screening tests for human immunodeficiency virus (HIV), hepatitis B (hep B), and hepatitis C (hep C) (referencing blood draw at leukapheresis screening); if positive results are not indicative of true active or chronic infection, the patient can be treatedXx_NEWLINE_xXCOHORT A: No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (negative screening tests required)Xx_NEWLINE_xXKnown active uncontrolled human immunodeficiency virus (HIV) or hepatitis C infectionXx_NEWLINE_xXSubjects with known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)Xx_NEWLINE_xXPositive human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infectionXx_NEWLINE_xXAs judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)Xx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positiveXx_NEWLINE_xXInfection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXSubjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C; viral testing is not required; subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollmentXx_NEWLINE_xXComorbidities or prior conditions:\r\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\r\n* Prior organ transplantation including allogenic stem-cell transplantation\r\n* Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy\r\n* Known history of active TB (Tuberculosis)\r\n* Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome\r\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening or positive serologies indicating prior infection\r\n* Active infection requiring systemic therapy\r\n* Has evidence of interstitial lung disease or active, non-infectious pneumonitis\r\n* Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medicationXx_NEWLINE_xXActive hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXActive human immunodeficiency virus (HIV) or hepatitis B or C with positive viral load, requiring anti-viral therapyXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or active hepatitis B or C viral infectionXx_NEWLINE_xXSubjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.Xx_NEWLINE_xXKnown seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible; patients who are seropositive for HCV, but have a negative viral load are also eligible; documentation that the patients have completed a course of therapy for HCV is required and will be obtainedXx_NEWLINE_xXActive hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXPatients must not have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infectionXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) or hepatitis B and/or C positive are not eligible for participation; NOTE: HIV and hepatitis testing is not required for study participationXx_NEWLINE_xXSubjects with known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV), because eltrombopag is hepatically cleared, and underlying hepatic impairment may lead to an increased risk of hepatotoxicity. Eltrombopag has not been evaluated with combination antiretroviral regimens.Xx_NEWLINE_xXDONOR: Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibioticsXx_NEWLINE_xXPatients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitisXx_NEWLINE_xXActive hepatitis B or C virus infection, or known human immunodeficiency virus(HIV) positiveXx_NEWLINE_xXKnown positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.Xx_NEWLINE_xXA known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitisXx_NEWLINE_xXSeroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) I or II, hepatitis B virus (HBV), hepatitis C virus (HCV)Xx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), active hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown infection with human immunodeficiency virus, Hepatitis B, or Hepatitis CXx_NEWLINE_xXActive or chronic systemic infection, including viral hepatitis, human immunodeficiency virus (HIV), mycobacteria, tuberculosis (TB), or other opportunistic infectionsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or active hepatitis B or C infectionXx_NEWLINE_xXPositive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXDocumentation of hepatitis B virus and hepatitis C virus serology is requiredXx_NEWLINE_xXClinical evidence of active infection of any type, including hepatitis B or C virusXx_NEWLINE_xXKnown hepatitis B virus, hepatitis C virus or HIV infection;Xx_NEWLINE_xXKnown seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXKnown prior positivity for active human immunodeficiency virus (HIV) or infectious hepatitis, type B or CXx_NEWLINE_xXKnown hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosisXx_NEWLINE_xXKnown or tests positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B or hepatitis C.Xx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or CXx_NEWLINE_xXPatients with a known history of infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXOngoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitisXx_NEWLINE_xXActive human immunodeficiency virus (HIV), hepatitis B and hepatitis CXx_NEWLINE_xXActive human immunodeficiency virus (HIV), hepatitis A, B or C infectionXx_NEWLINE_xXNegative serology tests for human immunodeficiency virus (HIV) Ab/Ag Combo, and for active hepatitis B or hepatitis C, within 14 days of first peripheral blood collection for sipuleucel-TXx_NEWLINE_xXActive human immunodeficiency virus 1 (HIV-1), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infectionXx_NEWLINE_xXInfection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXClinically relevant active infection including active hepatitis B or C or human immunodeficiency virus (HBV, HCV, or HIV) or any other concurrent diseaseXx_NEWLINE_xXNo additional screening intended for human immunodeficiency virus (HIV) or hepatitis infectionXx_NEWLINE_xXKnown chronic infection with human immunodeficiency virus (HIV) or viral hepatitisXx_NEWLINE_xXKnown history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or CXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown or suspected human immunodeficiency virus (HIV), hepatitis B surface antigen-positive status or known or suspected active hepatitis C infection.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B and hepatitis C (testing is not necessary if patient does not have history of these diseases, and no risk factors for acquisition of these viruses)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection, hepatitis B or Hepatitis C infectionXx_NEWLINE_xXDocumented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infectionXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.Xx_NEWLINE_xXPresence of active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, history of human immunodeficiency virus (HIV), or other uncontrolled systemic infectionXx_NEWLINE_xXPatients with a history of human immunodeficiency virus (HIV) infection; active viral infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)Xx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or CXx_NEWLINE_xXKnown active infection, or on antiretroviral therapy for human immunodeficiency virus (HIV) disease or positive test for chronic hepatitis B or C infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)Xx_NEWLINE_xXActive severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set in inclusion criteria number 8c, “hepatic function”Xx_NEWLINE_xXKnown positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infectionXx_NEWLINE_xXComorbid conditions: Addison’s disease, autoimmune hepatitis, hepatitis B, hepatitis C, acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV), lupus erythematosus, mixed connective tissue disease, rheumatoid arthritisXx_NEWLINE_xXNo known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients should be assessed for high risk behaviors that may result in these infections, such as intravenous drug use or multiple sexual partners; the assessment should be notedXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV-I), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)Xx_NEWLINE_xXNo known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicionXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or other viral hepatitis or cirrhosis from any causeXx_NEWLINE_xXActive hepatitis C or positive tests for human immunodeficiency virus (HIV)Xx_NEWLINE_xXNo known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXActive hepatitis or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C infection are ineligibleXx_NEWLINE_xXHave active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies) Screening is not required for enrollmentXx_NEWLINE_xXKnown seropositive for an active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.Xx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer)Xx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV), hepatitis B, or hepatitis C positiveXx_NEWLINE_xXSeropositive for human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) per patient historyXx_NEWLINE_xXMATCHED RELATED DONOR: Donors must be human immunodeficiency virus (HIV) negative, human T-cell lymphotropic virus (HTLV) negative, hepatitis B virus surface antigen (HBsAg) negativeXx_NEWLINE_xXPositive test results for human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV1), hepatitis C or chronic hepatitis BXx_NEWLINE_xXSeronegativity for human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV1), hepatitisXx_NEWLINE_xXPatients known to be seropositive for human immunodeficiency virus (HIV) and/or active hepatitis, even if liver function studies are in the eligible rangeXx_NEWLINE_xXKnown positivity for human immunodeficiency virus (HIV) or hepatitis C with uncontrolled disease; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or CXx_NEWLINE_xXHuman immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXPatient is known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B, or CXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis b virus vaccine are eligibleXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV) or an active and uncontrolled infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)Xx_NEWLINE_xXKnown active hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency virus (HIV) infections; Note: pretesting is not requiredXx_NEWLINE_xXActive hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXNegative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), and hepatitis CXx_NEWLINE_xXPatients with known active viral hepatitis or known human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infectionXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B (HBV) or C (HCV) or active hepatitisXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) infection.Xx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), and/or active Hepatitis C Virus (HCV) infection.Xx_NEWLINE_xXNo known human immunodeficiency virus (HIV) infection or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown history of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXEvidence of infection with human immunodeficiency virus (HIV) or viral hepatitisXx_NEWLINE_xXDONOR: Virology testing including cytomegalovirus (CMV), human immunodeficiency virus (HIV), Epstein–Barr virus (EBV), human T-lymphotropic virus (HTLV), rapid plasma reagin (RPR), hepatitis A, B and C will be performed within 30 days of donationXx_NEWLINE_xXActive and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.Xx_NEWLINE_xXKnown active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXPositive for HIV (Human Immunodeficiency Virus) or with active hepatitis B and/or CXx_NEWLINE_xXSubjects known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.Xx_NEWLINE_xXKnown positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infectionXx_NEWLINE_xXIs positive for Human Immunodeficiency Virus (HIV) and/or Hepatitis B or CXx_NEWLINE_xXKnown history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibioticsXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.Xx_NEWLINE_xXActive hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screeningXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis B/CXx_NEWLINE_xXHIV or human T-lymphotropic virus (HTLV) I/II positive, hepatitis C or chronic active hepatitis BXx_NEWLINE_xXActive severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters setXx_NEWLINE_xXActive, uncontrolled bacterial, fungal or viral infection, including hepatitis B, hepatitis C, known human immunodeficiency virus or acquired immunodeficiency syndrome related illness.Xx_NEWLINE_xXKnown active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infections. Subjects with laboratory evidence of HBV clearance may be enrolledXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXKnown active infection with human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXActive infection with Hepatitis B virus or Hepatitis C virusXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infectionXx_NEWLINE_xXHave a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active HCV, active autoimmune disorder or disease requiring high dose of steroidsXx_NEWLINE_xXDocumented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment (note: for guidance in defining active infection for hepatitis B, please refer to the WHO guidelines)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) and/or active Hepatitis B or C infectionsXx_NEWLINE_xXUncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXSeropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosisXx_NEWLINE_xXKnown ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXAlso, known human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXHas known, previously diagnosed human immunodeficiency virus infection or active chronic hepatitis B or C.Xx_NEWLINE_xXKnown diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis CXx_NEWLINE_xXOngoing or active systemic infection, history of hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXActive hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrierXx_NEWLINE_xXKnown history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infectionXx_NEWLINE_xXSubject has known historical or active infection with HIV (human immunodeficiency virus), hepatitis B, or hepatitis C or subject receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the Investigator, increase the risk of serious neutropenic complications.Xx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); HIV-positive patients on combination antiretroviral therapy are ineligibleXx_NEWLINE_xXActive infection requiring systemic therapy, including known human immunodeficiency virus (HIV), acquired immunodeficiency syndrome-related illness, or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.Xx_NEWLINE_xXAny known positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy; baseline testing is not requiredXx_NEWLINE_xXKnown clinically significant infections, including human immunodeficiency virus (HIV) and active hepatitis B or CXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis CXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXPts with known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) disease (routine testing is not needed if not clinical indicated)Xx_NEWLINE_xXDONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by NBAH Blood CenterXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both)Xx_NEWLINE_xXActive, life threatening or clinically significant uncontrolled systemic infection, known human immunodeficiency virus (HIV)-related illness, hepatitis B (Hep B) or hepatitis C (Hep C) infectionXx_NEWLINE_xXKnown confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (hepatitis B or hepatitis C)Xx_NEWLINE_xXpositive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C.Xx_NEWLINE_xXKnown ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXPatients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitisXx_NEWLINE_xXPatients with previously known infection with human immunodeficiency virus (HIV) or active viral hepatitis are ineligible; (diagnostic testing for these infections will be done only if clinically indicated)Xx_NEWLINE_xXOngoing or active infection including known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV); testing for these viruses is not required in the absence of a history of infectionXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV), or known active hepatitis B or C infectionsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness, active hepatitis B virus, or active hepatitis C virusXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXActive infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositiveXx_NEWLINE_xXPositive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence in the serum of the antigens HBsXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or hepatitis B or C infectionXx_NEWLINE_xXNegative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was performed during the previous 3 months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent form for HIV testingXx_NEWLINE_xXPatients with active hepatitis B or C infections or a history of human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV) or hepatitis B or CXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or CXx_NEWLINE_xXNegative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was performed during the previous 3 months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent form for HIV testingXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXActive symptomatic fungal, bacterial and/or viral infection including positive serologies for human immunodeficiency virus (HIV), H\\human T-lymphotropic virus 1 (HTLV-1), 2, hepatitis C virus (HCV) or hepatitis B virus (HBV) (acute or chronic infection based on Center for Disease Control and Prevention [CDC] guidelines) within 30 days of registration; (antibody, antigen and nucleic acid tests acceptable, depending on institutional standards)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; must test during screening if history is not knownXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.Xx_NEWLINE_xXSerious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C (NOTE: testing is not required)\r\n* Known human immunodeficiency virus (HIV) infection (NOTE: testing is not required)\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of first dose of mirvetuximab soravtansineXx_NEWLINE_xXClinically significant infections including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or CXx_NEWLINE_xXHave known fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (B or C);Xx_NEWLINE_xXKnown to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virusesXx_NEWLINE_xXClinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXPreviously known infection with human immunodeficiency virus (HIV); or, hepatitis B or C requiring treatment;Xx_NEWLINE_xXKnown and actively treated infection with human immunodeficiency virus (HIV), hepatitis B or CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) or active hepatitis B or C infectionXx_NEWLINE_xXActive severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virusXx_NEWLINE_xXInfection with Human immunodeficiency virus (HIV) or hepatitis B virus, hepatitis C\n             virusXx_NEWLINE_xXKnown sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.Xx_NEWLINE_xXActive hepatitis B and C virus infectionXx_NEWLINE_xXHepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)-positive participants with active infectionXx_NEWLINE_xXPatients with known active hepatitis B, C or human immunodeficiency virus (HIV) infections on initial assessmentXx_NEWLINE_xXKnown active human immunodeficiency virus (HIV) infection, hepatitis B or CXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients with prior exposure to hepatitis, but no evidence of active or chronic infection, may be eligibleXx_NEWLINE_xXKnown active infection with hepatitis A, B or C virusXx_NEWLINE_xXSubject with known hepatitis B surface antigen (HBsAg) positive status; or known or suspected active hepatitis C infection; or known human immunodeficiency virus (HIV) positive.Xx_NEWLINE_xXKnown or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis CXx_NEWLINE_xXKnown infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); testing may have been done up to 3 months prior to treatmentXx_NEWLINE_xXInfection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressiveXx_NEWLINE_xXSubject has a known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.Xx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXActive hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrierXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or CXx_NEWLINE_xXPatient with known historical or active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXKnown human immunodeficiency virus infection, or hepatitis B virus (HBV) viremia or hepatitis C virus (HCV) viremia; screening for the study does not require assessment for these infections if not already known; any other condition that, in the opinion of the investigator, may compromise the safety, compliance of the patient, or would preclude the patient from successful completion of the studyXx_NEWLINE_xXKnown history of infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)Xx_NEWLINE_xXAcute hepatitis, known human immunodeficiency virus (HIV), or active uncontrolled infectionXx_NEWLINE_xXPatients with any evidence of severe or uncontrolled systemic disease(s) including known cases of hepatitis B or C or human immunodeficiency virus (HIV); screening for chronic conditions is not required, although patients known to have such conditions at screening should not be includedXx_NEWLINE_xXKnown positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.Xx_NEWLINE_xXA history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection.Xx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).Xx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXSubjects who are known to have a history of or active human immunodeficiency virus (HIV) or active hepatitis B and/or CXx_NEWLINE_xXHave known hepatitis B or C, or human immunodeficiency virus infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection or chronic hepatitis B or C; negative screening tests for HIV, hepatitis B, and hepatitis C are requiredXx_NEWLINE_xXKnown positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.Xx_NEWLINE_xXNo infection with human immunodeficiency virus (HIV) and no active infection with hepatitis B and no active or chronic infection with hepatitis CXx_NEWLINE_xXKnown hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXKnown to be positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXA history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infectionXx_NEWLINE_xXConcomitant diseases/conditions as unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with left ventricular ejection fraction (LVEF) ? 50%, dyspnea, infection by human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the patient's ability to comply with the treatment or to follow-up the protocol, any other major illnessXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV), hepatitis B or C (however, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)Xx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXNo human immunodeficiency virus (HIV) infection, active hepatitis B infection, or active hepatitis C infectionXx_NEWLINE_xXKnown seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).Xx_NEWLINE_xXKnown active hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection.Xx_NEWLINE_xXKnown intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditionsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXPatients with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.Xx_NEWLINE_xXCurrent known active infection with human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C virus; for patients who are known carriers of hepatitis B virus (HBV), active hepatitis B infection must be ruled out based on negative serologic testing and/or determination of HBV deoxyribonucleic acid (DNA) viral load per local guidelinesXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion.Xx_NEWLINE_xXActive Human Immunodeficiency Virus (HIV) or hepatitis B or C infectionXx_NEWLINE_xXKnown diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is not mandatory for study entry)Xx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection)Xx_NEWLINE_xXKnown history of hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis. Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease.Xx_NEWLINE_xXPatients with a history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXPatients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded because of potential effects on immune function and/ or possible drug interactionsXx_NEWLINE_xXPatients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections are excludedXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virusXx_NEWLINE_xXKnown positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen.Xx_NEWLINE_xXInfection with human immunodeficiency virus, hepatitis B, or hepatitis CXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B.Xx_NEWLINE_xXSubjects may not have known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infectionXx_NEWLINE_xXSeropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).Xx_NEWLINE_xXThe patient has known positive status for human immunodeficiency virus (HIV), active or chronic Hepatitis B or Hepatitis C.Xx_NEWLINE_xXCurrent evidence or previous medical history of (ie, any absolute risk of latent infection) hepatitis B or C, any active hepatitis, or human immunodeficiency virus (HIV) infection. Active clinically serious infections > CTCAE Grade 2.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXHepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled).Xx_NEWLINE_xXAny evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation (CD)4 count, not requiring antiretroviral medication will not be excludedXx_NEWLINE_xXKnown active infection with HIV, Hepatitis B or C virusXx_NEWLINE_xXKnown active hepatitis B virus infectionXx_NEWLINE_xXEvidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.Xx_NEWLINE_xXHepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or C infectionXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline testing for HIV and hepatitis C is not requiredXx_NEWLINE_xXKnown positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXHas Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXNo active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) positivity or active infectious hepatitis A, B or CXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive statusXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required; this is due to the unknown effects of AMG102Xx_NEWLINE_xXPatients known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C requiring active therapy (hepatitis B seropositivity due to hepatitis [Hep] B virus vaccine is not an exclusion); patients on combination antiviral therapy are ineligible; appropriate studies will be undertaken in this patient populationXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXA history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; testing for these is not required at baselineXx_NEWLINE_xXKnown human immunodeficiency virus, Hepatitis B or Hepatitis C infection.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; active hepatitis B or CXx_NEWLINE_xXUncontrolled infection, including human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), hepatitis B or hepatitis C viremiaXx_NEWLINE_xXClinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXPatients with human immunodeficiency virus infection, hepatitis B, or hepatitis C due to confounding effects on immune systemXx_NEWLINE_xXPatients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection due to confounding effects on immune functionXx_NEWLINE_xXPatients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or chronic hepatitis B or CXx_NEWLINE_xXKnown positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.Xx_NEWLINE_xXCurrently known active infection with HIV, hepatitis B or C virusXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infectionXx_NEWLINE_xXKnown evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infectionXx_NEWLINE_xXActive infection including tuberculosis (TB), hepatitis B, hepatitis C, or human immunodeficiency virus. Note: TB testing will be at the discretion of the treating physician and should be in line with local practiceXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active hepatitis C Virus or active hepatitis B virus infection or any uncontrolled active systemic infectionXx_NEWLINE_xXPositive history of human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infectionXx_NEWLINE_xXPatients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: \r\n* Ongoing or active infection requiring systemic treatment\r\n* Symptomatic congestive heart failure (>= class 3)\r\n* Unstable angina pectoris\r\n* Cardiac arrhythmia\r\n* Psychiatric illness/social situations that would, in the investigator’s opinion, limit compliance with study requirements\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Known John Cunningham virus (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML)\r\n* Known clinically active hepatitis A, B, or C infections\r\n** NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection may enroll if other laboratory criteria are met; those with HBV surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy for the duration of enrollment in the trial\r\n* Second malignancy that requires active treatment\r\n* Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpointsXx_NEWLINE_xXKnown hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients with clinically significant infection, including known human immunodeficiency virus (HIV), human herpesvirus-8 (HHV-8), hepatitis C infection, or known hepatitis B surface antigen positivity are not eligibleXx_NEWLINE_xXKnown (historical) positive human immunodeficiency virus (HIV) serology, active hepatitis B, or active hepatitis C infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection; active hepatitis B infection; active hepatitis C infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)Xx_NEWLINE_xXActive hepatitis C virusXx_NEWLINE_xXPatients with active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXHave an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies)Xx_NEWLINE_xXHas a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infectionXx_NEWLINE_xXActive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.Xx_NEWLINE_xXPatients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV); the use of physiologic doses of corticosteroids may be approved after consultation with the study chairXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening)Xx_NEWLINE_xXActive infection (such as human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make corticosteroid use contraindicatedXx_NEWLINE_xXActive hepatitis B or C virusXx_NEWLINE_xXActive infection requiring systemic therapy, known human immunodeficiency virus infection, or positive test for hepatitis B active infection or hepatitis C active infection.Xx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis CXx_NEWLINE_xXKnown chronic active hepatitis B or hepatitis C; human immunodeficiency virus (HIV)-positive patients receiving or are candidates for antiretroviral therapy are also excludedXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection or viral hepatitisXx_NEWLINE_xXNo known history of human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXDONOR: Human T-cell lymphotropic virus (HTLV)/human immunodeficiency virus (HIV)(+) or hepatitis B or C antigen(+) donorsXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related diseaseXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registrationXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registrationXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown seropositive, requiring anti-viral therapy, and with detectable viral load by polymerase chain reaction (PCR) for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXHuman Immunodeficiency Virus, Hepatitis B Virus or Hepatitis C Virus infection.Xx_NEWLINE_xXPast history of tuberculosis (TB) or active infection with TB, human immunodeficiency virus (HIV), hepatitis B or hepatitis C.Xx_NEWLINE_xXHave a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infectionXx_NEWLINE_xXAny positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infectionXx_NEWLINE_xXPatient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic testsXx_NEWLINE_xXActive infection with Hepatitis B virus or Hepatitis C virusXx_NEWLINE_xXKnown seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXKnown positivity for human immunodeficiency virus (HIV) or active hepatitis B or CXx_NEWLINE_xXKnown seropositivity for human immunodeficiency virus (HIV) or diagnosis of acquired immunodeficiency syndrome (AIDS), positive for hepatitis B surface antigen, or seropositive for hepatitis C virusXx_NEWLINE_xXPatients with a diagnosis of hepatitis or human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients with known active hepatitis B, hepatitis C, or seropositive human immunodeficiency virus (HIV); testing is not required in the absence of clinical suspicionXx_NEWLINE_xXHistory of or current human immunodeficiency virus (HIV) or hepatitis C virus infectionXx_NEWLINE_xXHistory of known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXActive/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infectionXx_NEWLINE_xXHistory of known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis CXx_NEWLINE_xXOngoing hepatitis B virus (HBV) infectionXx_NEWLINE_xXKnown history of or known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis CXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis CXx_NEWLINE_xXDONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T?cell lymphotropic virus (HTLV?I/II)Xx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV); this information will be obtained verbally from the patientXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV) or active hepatitis CXx_NEWLINE_xXHistory of human immunodeficiency virus (HIV), hepatitis B, or active hepatitis C infectionXx_NEWLINE_xXEvidence of any active uncontrolled infection (bacterial, viral or fungal) or evidence of natural exposure to hepatitis B, hepatitis C or human immunodeficiency virus (HIV) without demonstration of polymerase chain reaction (PCR) negativity for said virus; vaccination to hepatitis B is not an exclusion criterionXx_NEWLINE_xXDONOR: All donors will be screened for the following:\r\n* Human immunodeficiency virus (HIV) I\r\n* HIV II\r\n* Hepatitis surface antigen (HbsAg)\r\n* Hepatitis B core antibody (HBc)\r\n* Hepatitis C virus (HCV)\r\n* Cytomegalovirus (CMV)\r\n* Syphilis\r\n* Human T-lymphotropic virus (HTLV I/II)\r\n* Epstein-Barr virus (EBV) and adenovirus immunoglobulin G (IgG) when feasibleXx_NEWLINE_xXPositive viral test of the donor for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV) 1 (if tested), HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested)Xx_NEWLINE_xXKnown serious infections, including a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for these infections is not required for study enrollmentXx_NEWLINE_xXPositive for human immunodeficiency virus (HIV) or active infections for hepatitis B, and/or hepatitis C, based on medical historyXx_NEWLINE_xXKnown active infection with human immunodeficiency virus (HIV), hepatitis A, B, or CXx_NEWLINE_xXSubjects with positive human immunodeficiency virus (HIV) or hepatitis C at baselineXx_NEWLINE_xXKnown to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virusesXx_NEWLINE_xXKnown Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infectionXx_NEWLINE_xXKnown human immuno virus infection.Xx_NEWLINE_xXSubjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV) infection.Xx_NEWLINE_xXKnown hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medicationsXx_NEWLINE_xXKnown immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus [HIV], hepatitis)Xx_NEWLINE_xXHistory of or active hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXKnown hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) positivity with evidence of ongoing infection.Xx_NEWLINE_xXSubject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B, or active hepatitis A or CXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive or active hepatitisXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)Xx_NEWLINE_xXDocumented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C =< 1 year prior to registrationXx_NEWLINE_xXSubjects must not have a history of human immunodeficiency virus, hepatitis B, or hepatitis C, except for the following:Xx_NEWLINE_xXKnown positive status for human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).Xx_NEWLINE_xXPatients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligibleXx_NEWLINE_xXPatient has a known history of human immunodeficiency virus (HIV) or active hepatitis B or active hepatitis C infection (testing not mandatory)Xx_NEWLINE_xXPatients who have a known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)Xx_NEWLINE_xXIs known to be human immunodeficiency virus (HIV) positive and/or known to have active chronic or acute Hepatitis B or Hepatitis CXx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illnessXx_NEWLINE_xXKnown active hepatitis B/C or HIV (human immunodeficiency virus) infectionXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV), or active Hepatitis B or C.Xx_NEWLINE_xXKnown positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infectionXx_NEWLINE_xXOngoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positiveXx_NEWLINE_xXActive systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])Xx_NEWLINE_xXActive viral hepatitis or symptomatic human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXParticipants with known human immunodeficiency virus (HIV) infection, hepatitis B carrier state or with clinical evidence of hepatitis BXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), active Hepatitis B (HBV) or Hepatitis C (HCV) infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted)Xx_NEWLINE_xXHave a serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus [HIV], hepatitis C virus [HCV], hepatitis B virus [HBV] [ie, positive hepatitis B surface antigen [+HBsAg]]), or an autoimmune disease.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)Xx_NEWLINE_xXActive chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active HIV, or cytomegalovirus (CMV) infection.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.Xx_NEWLINE_xXHas acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.Xx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).Xx_NEWLINE_xXIs previously diagnosed human immunodeficiency virus (HIV) infection or active hepatitis B or C.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection (Exception: Subjects with chronic or cleared HBV and HCV infection and stable liver function tests [bilirubin, AST] will be allowed)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV), recent hepatitis B virus (HBV), hepatitis C virus (HCV)Xx_NEWLINE_xXClinically significant history of liver disease (including cirrhosis), current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virusXx_NEWLINE_xXHuman immunodeficiency virus (HIV), or active hepatitis B or C infectionXx_NEWLINE_xXHistory of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)Xx_NEWLINE_xXKnown, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)Xx_NEWLINE_xXHas acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.Xx_NEWLINE_xXKnown seropositive for human immunodeficiency (HIV) virus, hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV).Xx_NEWLINE_xX